Compare HAS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | DVA |
|---|---|---|
| Founded | 1923 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 14.9B |
| IPO Year | 1994 | 2003 |
| Metric | HAS | DVA |
|---|---|---|
| Price | $87.74 | $178.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | $109.73 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.2M | 579.6K |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.51 | ★ 6.86 |
| Revenue | $5,365,900,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $5.38 | $3.85 |
| Revenue Next Year | $6.48 | $3.07 |
| P/E Ratio | $34.59 | ★ $25.46 |
| Revenue Growth | ★ 13.06 | 6.46 |
| 52 Week Low | $69.50 | $101.00 |
| 52 Week High | $106.98 | $247.49 |
| Indicator | HAS | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 42.43 |
| Support Level | $83.50 | $173.99 |
| Resistance Level | $89.20 | $202.63 |
| Average True Range (ATR) | 2.06 | 5.47 |
| MACD | -0.42 | 0.22 |
| Stochastic Oscillator | 32.53 | 19.52 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to around 20 million digital tabletop players.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.